RELX PLC: Stock Analysis and Future Predictions

Aug.26.2022
RELX PLC: Stock Analysis and Future Predictions
RELX stock falls slightly to $28.04, with average trading volume of 891,300 shares. Analysts rate it a "buy".

RELX PLC, trading on the New York Stock Exchange as RELX, closed at $28.04 on Wednesday with no change from the previous day's closing price. The average trading volume over the past five days was 891,300 shares. The stock price decreased by $0.82 in the past week, although it has reached a 17-fold high in the last 12 months. The average trading volume over the past 20 days was 660,680 shares, while the 50-day average trading volume was 1,016,512 shares.

 

Last month, shares of RELX fell by 0.85%. The company's stock reached its lowest point of $27.84 per share on August 23, 22. After rebounding to a 52-week high of $32.71 on January 3, the stock hit a low of $24.81 within the 52-week period. So far this year, the stock has reached a new high but has since dropped by 14.01% or $4.57. Despite this, the price is still down 14.28% from its 52-week high.

 

Valuation Metrics

 

The trailing P/E ratio for RELX PLC (RELX) is 29.06. Its beta is 0.74. Other valuation ratios to consider include a P/S ratio of 5.84, a PB ratio of 12.41, and a price-to-cash-flow ratio of 42.80.

 

The company's payout ratio stands at 52.60%. The latest quarterly dividend paid by the company was $0.4443 per share, which reflects a decline of 7.82% compared to the previous year's $0.4820 per share. The most recent dividend decrease of $0.0377 per share was announced on Friday, July 29, 2022.

 

Financial Health

 

Recently, the quick ratio of RELX PLC for the quarter was 0.50 and the current ratio is also 0.50, indicating that the company may not be able to fulfill its debts. Additionally, the company's long-term debt to equity ratio for the recent quarter was 1.63, and the total debt to equity ratio was 1.89. RELX PLC's EBITDA profit margin was 35.31%, while the operating profit margin for the same period was 27.10%. It has been reported that the company's total profit is $6.44 billion and its revenue is $9.96 billion.

 

Profit Surprises

 

The company had a net income of 1.47 billion USD for this quarter, with a revenue growth of 16.79%.

 

From a technical analysis perspective, let's take a brief look at the price trends of RELX PLC (RELX). As of the close on August 24th, the 9-day RSI was 31.06%, indicating the stock is neutral, and the historical volatility during this timeframe was 10.78%.

 

As of today, the price of RELX is $28.49, a decrease of 2.84% compared to its five-day moving average of $0.82. RELX's current trading price is 2.37% lower than its 20-day simple moving average and 9.84% lower than its 100-day SMA. However, its current price is higher than its 50-day SMA by 7.72% but lower than its 200-day SMA by 11.60%.

 

The random values for K and D are 8.36% and 10.25% respectively, with an average true range (ATR) of 0.36. Over a 14-day period, the random value is 11.30% with an average true range of 0.38, while the RSI (14) is 41.09%. The stock's 9-day MACD oscillator has reached -0.46, while the reading for 14 days is -0.59.

 

Analyst rating.

 

Kepler has upgraded RELX PLC (NYSE code: RELX) to a buy rating in its latest analyst report. Previously, the stock was rated as hold. The consensus rating for RELX PLC (RELX) among analysts is overweight. According to current broker recommendations, zero brokerage firms suggest selling RELX while two suggest holding. There are no analysts who rate the stock as underweight. The stock is rated as overweight by zero analysts while one other analyst rates it as a buy.

 

What is RELX's price target for the next 12 months?

 

Analysts predict a target price range of $32.80 to $32.80, with a median target of $32.80 for RELX PLC (RELX) stock. Based on these predictions, the average target price given by analysts is $32.80.

 

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
2Firsts Data | China’s Vape-Related Exports Rise 16.5% in July 2026 as U.S.-Bound Shipments Jump 53.5%
China’s vape-related exports reached $1.047 billion in July 2026, up 16.5% year on year and the highest monthly total of the year. Growth was heavily concentrated in the U.S., where exports jumped 53.5% to $404 million and accounted for 94.9% of the overall increase. Exports to all other markets rose just 1.2%. By category, nicotine-containing non-combustible products—primarily vapes—under HS24041200 rose 24.7% and generated 95.5% of the total increase. Vape-device exports under HS85434000 fell 0.4%, while other nicotine-substitute products under HS24041990 grew 88.9% but remained comparatively small.
DATA
Aug.24
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation Proposes 75% Tobacco Tax Cut, Says Lower Prices Could Hit Illicit Market
Australia’s One Nation party has proposed cutting tobacco excise by 75%, arguing that lower legal cigarette prices could narrow the gap with illicit tobacco and reduce demand for black-market products. The proposal comes as Australia continues expanding enforcement against illicit tobacco supply chains through border controls, retail inspections and organised-crime investigations. Supporters argue high taxes have contributed to illicit-market growth, while opponents warn that lower tobacco prices could undermine public-health goals. The proposal is a party policy position and has not been adopted by the Australian government.
Aug.18
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22